• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Biotech

    Viridian`s Tepezza Rival Scores Ph. 3 Win, But Investors Unsure

    FIERCE BIOTECH

    Viridian Elegrobart Ph3 REVEAL-1 Shows Positive TED Topline Data

    BUSINESSWIRE

    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    BUSINESSWIRE

    Viridian Therapeutics Prepares for Transformational 2026

    BUSINESSWIRE

    Viridian Therapeutics Gets Priority Review For Veligrotug BLA

    BUSINESSWIRE

    Viridian Announces Inducement Grants Under Nasdaq LR 5635(c)(4)

    PHARMIWEB

    Viridian Therapeutics Issues Inducement Grants Per Nasdaq LR

    BUSINESSWIRE

    Viridian Therapeutics Unveils Q3 2025 Financials & Recent

    BUSINESSWIRE

    Viridian Pharma Prices $251M Public Stock Offering

    PHARMIWEB

    Viridian Therapeutics Plans Public Offering

    PHARMIWEB

    Viridian Completes Enrollment in REVEAL Clinical Trials

    BUSINESSWIRE

    Kissei Pays Viridian $70M to Compete with Amgen in Japan

    FIERCE BIOTECH

    Viridian`s Reports Positive Data from Veligrotug Ph 3 Trial

    BUSINESSWIRE

    Viridian Therapeutics gets FDA Breakthrough for Veligrotug in TED

    BUSINESSWIRE

    Viridian Therapeutics Reports First Quarter 2025 Results

    BUSINESSWIRE

    Viridian Highlights Progress & Reports Q4 & Full-Year 2024 Results

    BUSINESSWIRE

    Viridian Sets 2025 Goals After Positive Ph 3 Data In Eye Disease

    BUSINESSWIRE

    Viridian Therapeutic Announces Positive Veligrotug Phase 3 Results

    BUSINESSWIRE

    Viridian Therapeutics Reports Q3 2024 Financial Results & Progress

    BUSINESSWIRE

    Viridian Therapeutics Prices Upsized Public Offering Of Shares

    BUSINESSWIRE

    Viridian Therapeutics Reports Q2 2024 Results And Recent Progress

    BUSINESSWIRE

    Viridian Details VRDN-003 Phase 3 Program In Thyroid Eye Disease

    BUSINESSWIRE

    Viridian Announces Positive Data from Phase 1/2 Trial Evaluating VRDN-001

    BUSINESSWIRE

    Viridian looks to beat Horizon`s Tepezza in thyroid eye disease

    FIERCE BIOTECH

    Viridian Announces Positive Data from Phase 1/2 Trial Evaluating VRDN-001

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.